CpG-conjugated apoptotic tumor cells elicit potent tumor-specific immunity

Cancer Immunology, Immunotherapy

Volumn 60, Issue 5, 2011, Pages 659-669

  Shirota, Hidekazu ^a,b   Klinman, Dennis M ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Adjuvant; Cancer; CpG ODN; TLR9; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; CD69 ANTIGEN; INTERLEUKIN 12; TUMOR ANTIGEN; TUMOR CELL VACCINE; TUMOR CELL VACCINE CPG OLIGODEOXYNUCLEOTIDE CONJUGATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BREAST CARCINOMA; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG CONJUGATION; DRUG POTENCY; DRUG UPTAKE; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR IMMUNITY; UPREGULATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; CPG ISLANDS; CYTOKINES; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FLOW CYTOMETRY; IMMUNOTHERAPY; MICE; MICE, INBRED C57BL; NEOPLASM METASTASIS; NEOPLASMS; OLIGODEOXYRIBONUCLEOTIDES; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 79955547695     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0973-y     Document Type: Article

References (43)

1. SM Bae YW Kim SY Kwak YW Kim DY Ro JC Shin CH Park SJ Han CH Oh CK Kim WS Ahn 2007 Photodynamic therapy-generated tumor cell lysates with CpG-oligodeoxynucleotide enhance immunotherapy efficacy in human papillomavirus 16 (E6/E7) immortalized tumor cells Cancer Sci 98 747 752 17425690 10.1111/j.1349-7006.2007.00447.x 1:CAS:528:DC%2BD2sXkvFSku74%3D (Pubitemid 46563453)
2. D Berd HC Maguire Jr P McCue MJ Mastrangelo 1990 Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients J Clin Oncol 8 1858 1867 2230873 1:STN:280: DyaK3M%2FjvVWktA%3D%3D (Pubitemid 20382349)
3. L Chen P McGowan S Ashe J Johnston Y Li I Hellstrom KE Hellstrom 1994 Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity J Exp Med 179 523 532 7507508 10.1084/jem.179.2.523 1:CAS:528:DyaK2cXhtVCqu7w%3D
4. NR Chu HB Wu TC Wu LJ Boux LA Mizzen MI Siegel 2000 Immunotherapy of a human papillomavirus type 16 E7-expressing tumor by administration of fusion protein comprised of Mycobacterium bovis BCG Hsp65 and HPV16 E7 Cell Stress Chaperones 5 401 405 11189443 10.1379/1466-1268(2000)005<0401:IOAHPT>2.0. CO;2 1:CAS:528:DC%2BD3MXkslyhtQ%3D%3D (Pubitemid 32057489)
5. CL Cooper HL Davis ML Morris SM Efler MA Adhami AM Krieg DW Cameron J Heathcote 2004 CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study J Clin Immunol 24 693 701 15622454 10.1007/s10875-004-6244-3 1:CAS:528:DC%2BD2MXhtFSmsQ%3D%3D (Pubitemid 40933121)
6. J Copier A Dalgleish 2006 Overview of tumor cell-based vaccines Int Rev Immunol 25 297 319 17169778 10.1080/08830180600992472 1:CAS:528: DC%2BD2sXisl2ltg%3D%3D (Pubitemid 44972269)
7. CM Coughlin KE Salhany M Wysocka E Aruga H Kurzawa AE Chang CA Hunter JC Fox G Trinchieri WM Lee 1998 Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis J Clin Invest 101 1441 1452 9502787 10.1172/JCI1555 1:CAS:528:DyaK1cXitVWjtbs%3D (Pubitemid 28145262)
8. G Dranoff E Jaffee A Lazenby P Golumbek H Levitsky K Brose V Jackson H Hamada D Pardoll RC Mulligan 1993 Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity Proc Natl Acad Sci USA 90 3539 3543 8097319 10.1073/pnas.90.8.3539 1:CAS:528: DyaK3sXktVKqt78%3D (Pubitemid 23111402)
9. BA Foster JR Gingrich ED Kwon C Madias NM Greenberg 1997 Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model Cancer Res 57 3325 3330 9269988 1:CAS:528:DyaK2sXls1ShtLs%3D (Pubitemid 27355467)
10. JW Friedberg H Kim M McCauley EM Hessel P Sims DC Fisher LM Nadler RL Coffman AS Freedman 2005 Combination immunotherapy with a CpG oligonucleotide (1018 ISS) and rituximab in patients with non-Hodgkin lymphoma: increased interferon-alpha/beta-inducible gene expression, without significant toxicity Blood 105 489 495 15358617 10.1182/blood-2004-06-2156 1:CAS:528: DC%2BD2MXltlGisg%3D%3D (Pubitemid 40070726)
11. E Gilboa 2004 The promise of cancer vaccines Nat Rev Cancer 4 401 411 15122211 10.1038/nrc1359 1:CAS:528:DC%2BD2cXjsFSlu7s%3D (Pubitemid 38579486)
12. DR Green T Ferguson L Zitvogel G Kroemer 2009 Immunogenic and tolerogenic cell death Nat Rev Immunol 9 353 363 19365408 10.1038/nri2545 1:CAS:528:DC%2BD1MXksVyit7Y%3D
13. TF Greten EM Jaffee 1999 Cancer vaccines J Clin Oncol 17 1047 1060 10071300 1:CAS:528:DyaK1MXhvFGnsr4%3D (Pubitemid 29109339)
14. SA Halperin G Van Nest B Smith S Abtahi H Whiley JJ Eiden 2003 A phase I study of the safety and immunogenicity of recombinant hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide adjuvant Vaccine 21 2461 2467 12744879 10.1016/S0264-410X(03) 00045-8 1:CAS:528:DC%2BD3sXjs1Wls7s%3D (Pubitemid 36561337)
15. K Heckelsmiller K Rall S Beck A Schlamp J Seiderer B Jahrsdorfer A Krug S Rothenfusser S Endres G Hartmann 2002 Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model J Immunol 169 3892 3899 12244187 1:CAS:528:DC%2BD38XnsFeltb4%3D
16. A Heit F Schmitz M O'Keeffe C Staib DH Busch H Wagner KM Huster 2005 Protective CD8 T cell immunity triggered by CpG-protein conjugates competes with the efficacy of live vaccines J Immunol 174 4373 4380 15778402 1:CAS:528:DC%2BD2MXisVCht7k%3D (Pubitemid 40396020)
17. H Hemmi O Takeuchi T Kawai S Sato H Sanjo M Matsumoto K Hoshino H Wagner K Takeda S Akira 2000 A Toll-like receptor recognizes bacterial DNA Nature 408 740 745 11130078 10.1038/35047123 1:CAS:528:DC%2BD3cXptVCqsL0%3D (Pubitemid 32015992)
18. MA Hofmann C Kors H Audring P Walden W Sterry U Trefzer 2008 Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma J Immunother 31 520 527 18463532 10.1097/CJI.0b013e318174a4df 1:CAS:528:DC%2BD1cXmsFyrs7c%3D
19. DM Klinman 2004 Immunotherapeutic uses of CpG oligodeoxynucleotides Nat Rev Immunol 4 249 258 15057783 10.1038/nri1329 1:CAS:528:DC%2BD2cXis1GksLk%3D (Pubitemid 38478660)
20. AM Krieg A Yi S Matson TJ Waldschmidt GA Bishop R Teasdale GA Koretzky DM Klinman 1995 CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 546 548 7700380 10.1038/374546a0 1:CAS:528:DyaK2MXkvVKqtr8%3D
21. RA Lake BW Robinson 2005 Immunotherapy and chemotherapy-a practical partnership Nat Rev Cancer 5 397 405 15864281 10.1038/nrc1613 1:CAS:528:DC%2BD2MXjslertbk%3D (Pubitemid 40637831)
22. PL Lollini F Cavallo P Nanni G Forni 2006 Vaccines for tumour prevention Nat Rev Cancer 6 204 216 16498443 10.1038/nrc1815 1:CAS:528:DC%2BD28Xhsleltrk%3D (Pubitemid 43292564)
23. MW Moore FR Carbone MJ Bevan 1988 Introduction of soluble protein into the class I pathway of antigen processing and presentation Cell 54 777 785 3261634 10.1016/S0092-8674(88)91043-4 1:CAS:528:DyaL1cXmtV2hu74%3D
24. AJ Muller PA Scherle 2006 Targeting the mechanisms of tumoral immune tolerance with small-molecule inhibitors Nat Rev Cancer 6 613 625 16862192 10.1038/nrc1929 1:CAS:528:DC%2BD28XntFGlu7s%3D (Pubitemid 44140859)
25. S Nierkens MH den Brok RP Sutmuller OM Grauer E Bennink ME Morgan CG Figdor TJ Ruers GJ Adema 2008 In vivo colocalization of antigen and CpG [corrected] within dendritic cells is associated with the efficacy of cancer immunotherapy Cancer Res 68 5390 5396 18593941 10.1158/0008-5472.CAN-07-6023 1:CAS:528:DC%2BD1cXnvFyjtLg%3D
26. S Novakovic V Stegel A Kopitar A Ihan BJ Novakovic 2007 Preventive and therapeutic antitumor effect of tumor vaccine composed of CpG ODN class C and irradiated tumor cells is triggered through the APCs and activation of CTLs Vaccine 25 8241 8256 17980936 10.1016/j.vaccine.2007.09.067 1:CAS:528: DC%2BD2sXhtlahurrK (Pubitemid 350087387)
27. K Ohashi G Kobayashi S Fang X Zhu SJ Antonia AM Krieg AD Sandler 2006 Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma J Pediatr Surg 41 1361 1368 16863838 10.1016/j.jpedsurg.2006.04.034 (Pubitemid 44080244)
28. DM Pardoll 1995 Paracrine cytokine adjuvants in cancer immunotherapy Annu Rev Immunol 13 399 415 7612229 10.1146/annurev.iy.13.040195.002151 1:CAS:528:DyaK2MXltFamur8%3D
29. BA Pulaski DS Terman S Khan E Muller S Ostrand-Rosenberg 2000 Cooperativity of Staphylococcal aureus enterotoxin B superantigen, major histocompatibility complex class II, and CD80 for immunotherapy of advanced spontaneous metastases in a clinically relevant postoperative mouse breast cancer model Cancer Res 60 2710 2715 10825145 1:CAS:528:DC%2BD3cXjsF2gtb4%3D (Pubitemid 30318248)
30. AD Sandler H Chihara G Kobayashi X Zhu MA Miller DL Scott AM Krieg 2003 CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma Cancer Res 63 394 399 12543793 1:CAS:528:DC%2BD3sXnt1KrsQ%3D%3D (Pubitemid 36152498)
31. K Sano H Shirota T Terui T Hattori G Tamura 2003 Oligodeoxynucleotides without CpG motifs work as adjuvant for the induction of Th2 differentiation in a sequence-independent manner J Immunol 170 2367 2373 12594259 1:CAS:528:DC%2BD3sXht12hsbo%3D (Pubitemid 36245623)
32. H Shirota K Sano N Hirasawa T Terui K Ohuchi T Hattori K Shirato G Tamura 2001 Novel roles of CpG oligodeoxynucleotides as a leader for the sampling and presentation of CpG-tagged antigen by dendritic cells J Immunol 167 66 74 11418633 1:CAS:528:DC%2BD3MXkslSqtL0%3D (Pubitemid 32567762)
33. H Shirota K Sano N Hirasawa T Terui K Ohuchi T Hattori G Tamura 2002 B cells capturing antigen conjugated with CpG oligodeoxynucleotides induce Th1 cells by elaborating IL-12 J Immunol 169 787 794 12097381 1:CAS:528: DC%2BD38XlsVSqu7s%3D (Pubitemid 34753434)
34. H Shirota K Sano T Kikuchi G Tamura K Shirato 2000 Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs Am J Respir Cell Mol Biol 22 176 182 10657938 1:CAS:528:DC%2BD3cXhtlyht74%3D (Pubitemid 30351480)
35. H Shirota K Sano T Kikuchi G Tamura K Shirato 2000 Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator J Immunol 164 5575 5582 10820231 1:CAS:528:DC%2BD3cXjslemsLg%3D (Pubitemid 30389796)
36. EL Smits P Ponsaerts ZN Berneman TV Van 2008 The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy Oncologist 13 859 875 18701762 10.1634/theoncologist.2008-0097 1:CAS:528:DC%2BD1cXhtF2qs7vL
37. S Stevanovic 2002 Identification of tumour-associated T-cell epitopes for vaccine development Nat Rev Cancer 2 514 520 12094237 10.1038/nrc841 1:CAS:528:DC%2BD38XkvFKltLk%3D (Pubitemid 37336518)
38. T Switaj A Jalili AB Jakubowska N Drela M Stoksik D Nowis G Basak J Golab PJ Wysocki A Mackiewicz A Sasor K Socha M Jakobisiak W Lasek 2004 CpG immunostimulatory oligodeoxynucleotide 1826 enhances antitumor effect of interleukin 12 gene-modified tumor vaccine in a melanoma model in mice Clin Cancer Res 10 4165 4175 15217954 10.1158/1078-0432.CCR-04-0022 1:CAS:528:DC%2BD2cXltFWmu7g%3D (Pubitemid 38812497)
39. F Takeshita CA Leifer I Gursel K Ishii S Takeshita M Gursel DM Klinman 2001 Cutting edge: role of toll-like receptor 9 in CpG DNA-induced activation of human cells J Immunol 167 3555 3558 11564765 1:CAS:528:DC%2BD3MXntFajs7s%3D (Pubitemid 32910795)
40. H Tighe K Takabayashi D Schwartz R Marsden L Beck J Corbeil DD Richman JJ Eiden HL Spiegelberg E Raz 2000 Conjugation of protein to immunostimulatory DNA results in a rapid, long-lasting and potent induction of cell-mediated and humoral immunity Eur J Immunol 30 1939 1947 10940883 10.1002/1521-4141(200007) 30:7<1939::AID-IMMU1939>3.0.CO;2-# 1:CAS:528:DC%2BD3cXlt1GisLk%3D (Pubitemid 30456190)
41. GJ Weiner HM Liu JE Wooldridge CE Dahle AM Krieg 1997 Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization Proc Natl Acad Sci USA 94 10833 10837 9380720 10.1073/pnas.94.20.10833 1:CAS:528:DyaK2sXmtlChtrY%3D (Pubitemid 27430821)
42. A Wu S Oh S Gharagozlou RN Vedi K Ericson WC Low W Chen JR Ohlfest 2007 In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma J Immunother 30 789 797 18049330 10.1097/CJI.0b013e318155a0f6 1:CAS:528:DC%2BD2sXhtlGqs7bF (Pubitemid 350295357)
43. W Zou 2005 Immunosuppressive networks in the tumour environment and their therapeutic relevance Nat Rev Cancer 5 263 274 15776005 10.1038/nrc1586 1:CAS:528:DC%2BD2MXivVars7g%3D (Pubitemid 40488632)